Factual data · GO/NO-GO verdict · Financial model calibrated over 96 months
In Bobo-Dioulasso, pharmacy valuation is 80-110 % of revenue (90 % average), with a regulated gross margin of 26-32 %. New creation is extremely rare (transfer/merger only).
Dominant profile: industrielle
Competitive density: moderate (first-mover advantage possible).
Dominant players: regulated public-insurance sector, few private chains.
Positioning recommendation: Competitive positioning required: sector margin is tight, edge comes from operational efficiency.
| Indicator | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Year 1 revenue | 200.0 M FCFA → 590.0 M FCFA | ×1,18 (ramp-up) | ×1,32 (steady-state) |
| Target net margin | negative to low | 4 % | 10 % |
| Working capital (days of revenue) | 45-60 d | 35-50 d | 30-45 d |
| Cumulative ROI | investment | ~50 % | Payback at 96 months |
These ratios are calibrated on MarketLens sector benchmarks and adjusted by local coefficients of Bobo-Dioulasso, Burkina Faso (cost −62% vs average, income −80% vs average).
MarketLens combines AI market study, business plan calibrated for 24 countries, and post-launch monitoring. Everything exportable to PDF, PowerPoint, Excel and Word.